Korean J Urol Oncol.
2019 Apr;17(1):48-59. 10.22465/kjuo.2019.17.1.48.
The Treatment of Metastatic and Castration-Resistant Prostate Cancer Patients in Korea
- Affiliations
-
- 1Department of Urology, Daegu Catholic University Madical Center, Daegu, Korea.
- 2Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 3Department of Urology, Catholic Kwandong University International St. Mary's Hospital, Incheon, Korea.
- 4Department of Urology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 5Department of Urology, Konyang University College of Medicine, Daejeon, Korea.
- 6Department of Urology, Soonchunhyang University College of Medicine, Cheonan, Korea.
- 7Department of Urology, Inje University Seoul Paik Hospital, Seoul, Korea. yeoluvk@gmail.com
- KMID: 2448927
- DOI: http://doi.org/10.22465/kjuo.2019.17.1.48
Abstract
- The treatment of advanced prostate cancer has rapidly evolved. Androgen deprivation therapy is recognized as the first-line therapy for metastatic disease; however, a substantial proportion of patients will eventually progress to develop castration-resistance. For the past several years, docetaxel-based chemotherapy has shown significant therapeutic benefit in castration-resistant prostate cancer. Over the last 5 years, several new agents such as the enzalutamide, abiraterone, cabazitaxel, and 223radium have been developed which have all been associated with improved quality of life, pain palliation, and an increase in survival. Unfortunately, there are no Korean treatment guideline for metastatic prostate cancer and/or castration-resistant prostate cancer which has been developed based on adequate review and assessment of evidences. Thus, a guideline adequate for domestic circumstances is eagerly needed. The Korean Association for Clinical Oncology, the Korean Prostate Society, the Korean Urological Oncology Society, and the Korean Society of Pathologists reviewed and endorsed the guidelines.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Chemotherapy With Androgen Deprivation for Hormone-Naïve Prostate Cancer
- Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations
- The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer
- Long-Lasting Antiandrogen Withdrawal Syndrome in Castration-Resistant Prostate Cancer: Three Cases With Complete Response
- Precision Medicine in Castration-Resistant Prostate Cancer
